文献速递流行病学与生物统计真实世界研究与卫生经济

2015至2018年乳腺癌、宫颈癌和卵巢癌诊疗模式及至初始治疗时间的全球差异(VENUSCANCER):基于39个国家和地区103个人群癌症登记处275792名女性个人记录的二次分析

Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories.
PubMed 文献 · Lancet · 2025-10-22

VENUSCANCER项目二次分析纳入39个国家和地区103个人群癌症登记处2015至2018年单年发病的275792名乳腺癌、宫颈癌或卵巢癌女性的高分辨率个人记录。研究发现各国与ESMO、ASCO、NCCN指南一致的诊疗比例差异很大,高收入国家早期淋巴结阴性乳腺癌和宫颈癌占比超过40%而卵巢癌低于20%,中低收入国家这三类癌症该比例普遍低于20%。老年女性(70-99岁)接受指南一致初始治疗的比值比低于50-69岁女性,部分国家早期癌症诊断至治疗中位时间可达4个月甚至1年。

要点

  • 高收入国家早期淋巴结阴性乳腺癌和宫颈癌占比超过40%,卵巢癌低于20%;中低收入国家三类癌症该比例普遍低于20%。
  • 与指南一致的诊疗比例差异大:早期乳腺癌手术和放疗从格鲁吉亚13%到法国82%,晚期宫颈癌化疗从蒙古18%到加拿大90%,转移性卵巢癌手术加化疗从古巴9%到美国53%。
  • 高收入国家78%女性接受某种手术,中低收入国家为56%;70-99岁女性接受指南一致初始治疗的比值比低于50-69岁女性。

核心结论

  • VENUSCANCER项目首次提供全球女性三种最常见癌症诊疗模式的全景图,为WHO全球乳腺癌倡议和宫颈癌消除倡议等全球癌症控制举措的实施与监测提供关键真实世界证据。
  • 尽管中低收入国家早期肿瘤女性获得指南一致治疗的机会增加,但早期诊断比例仍远过低。

研究设计与样本

  • 这是一项基于人群癌症登记处匿名个人记录的二次分析(VENUSCANCER),纳入39个国家和地区103个登记处2015至2018年单年发病的乳腺癌、宫颈癌或卵巢癌女性高分辨率数据。
  • 高分辨率数据包括诊断时分期、分期检查、肿瘤分级、生物标志物(ER、PR、HER2)及每种治疗方式(手术、放疗、化疗、内分泌治疗或抗HER2治疗)的首次疗程及相关日期。
  • 分析按国家或地区考察预后因素、与国际临床指南(ESMO、ASCO、NCCN)一致性的关键指标及诊断至治疗的中位时间,并控制年龄和肿瘤亚型比较高收入国家与中低收入国家女性接受指南一致治疗的比值比。

主要发现

  • 共收到275792份匿名个人记录,其中乳腺癌214111份(77.6%)、宫颈癌44468份(16.1%,包括原位癌)、卵巢癌17213份(6.2%)。
  • 高收入国家早期淋巴结阴性乳腺癌和宫颈癌占比超过40%,卵巢癌低于20%;中低收入国家这三类癌症该比例普遍低于20%,但古巴乳腺癌为30%、俄罗斯宫颈癌为36%和卵巢癌为27%。
  • 与主要国际指南的一致性差异很大:早期乳腺癌手术和放疗从格鲁吉亚13%到法国82%,晚期宫颈癌化疗从蒙古18%到加拿大90%,转移性卵巢癌手术加化疗从古巴9%到美国53%。
  • 高收入国家78%女性接受某种手术,中低收入国家为56%;早期肿瘤指南一致初始治疗在宫颈癌和卵巢癌中比乳腺癌更趋一致。
  • 高收入国家和中低收入国家中,70-99岁女性接受指南一致初始治疗的比值比均低于50-69岁女性;早期癌症诊断至治疗中位时间在多个高收入国家不足1个月,但蒙古宫颈癌和厄瓜多尔卵巢癌可达4个月,蒙古乳腺癌可达1年。

关键数值与推荐

  • 指南一致性关键指标包括早期乳腺癌手术和放疗(格鲁吉亚13%至法国82%)、晚期宫颈癌化疗(蒙古18%至加拿大90%)、转移性卵巢癌手术加化疗(古巴9%至美国53%)。
  • 高收入国家早期淋巴结阴性乳腺癌和宫颈癌占比超过40%、卵巢癌低于20%;中低收入国家三类癌症该比例普遍低于20%,古巴乳腺癌30%、俄罗斯宫颈癌36%和卵巢癌27%。
  • 高收入国家78%女性接受某种手术,中低收入国家56%。
  • 70-99岁女性接受指南一致初始治疗的比值比低于50-69岁女性(高收入国家和中低收入国家均如此)。
  • 早期癌症诊断至治疗中位时间在多个高收入国家不足1个月,蒙古宫颈癌和厄瓜多尔卵巢癌可达4个月,蒙古乳腺癌可达1年。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Cancers of the breast, cervix, and ovary are a major public health problem worldwide. Evaluating the consistency with clinical guidelines for treatment by use of individual high-resolution data from population-based cancer registries is a powerful tool to help interpretation of global inequalities in cancer survival. The VENUSCANCER project aims to assess the worldwide variation in patterns of care and time to initial treatment for women diagnosed with one of these three common cancers. METHODS: In this secondary analysis of anonymised individual records from population-based cancer registries (VENUSCANCER), 103 registries from 39 countries worldwide contributed high-resolution data for women diagnosed with cancer of the breast, cervix, or ovary for a single year of incidence during 2015-18. High-resolution data included cancer stage at diagnosis; staging procedures; tumour grade; biomarkers (ER, PR, and HER2); and the first course of each treatment modality (surgery, radiotherapy, chemotherapy, endocrine treatment, or anti-HER2 therapy) and related dates. We examined prognostic factors, key indicators of consistency with international clinical guidelines for treatment (ESMO, ASCO, and NCCN), and median time between diagnosis and treatment, by country or territory. We analysed the odds of women receiving treatment consistent with guidelines in high-income countries (HICs) and low-income and middle-income countries (LMICs), controlling for age and tumour subtype. FINDINGS: We received 275 792 anonymised individual records for women diagnosed with a cancer of the breast (214 111 [77·6%]), cervix (44 468 [16·1%], including in situ), or ovary (17 213 [6·2%]). In HICs, early-stage, node-negative cancers comprised over 40% of breast and cervical cancers, but less than 20% of ovarian cancers. By contrast, in LMICs, these proportions were generally below 20% for all three cancers, but higher in Cuba (30% for breast), and Russia (36% for cervix and 27% for ovary). Consistency with main international guidelines was highly variable, particularly for surgery and radiotherapy in early-stage breast cancer (from 13% in Georgia to 82% in France), chemotherapy in advanced cervical cancer (from 18% in Mongolia to 90% in Canada), and surgery plus chemotherapy in metastatic ovarian cancer (from 9% in Cuba to 53% in the USA). Some type of surgery was offered to 78% of women in HICs and 56% of women in LMICs, but initial treatment that is consistent with clinical guidelines for early-stage tumours was followed more uniformly for cervical and ovarian cancer than for breast cancer. Older women (aged 70-99 years) had lower odds of receiving initial treatment consistent with clinical guidelines than women aged 50-69 years in both HICs and LMICs. The median time between diagnosis and treatment for early-stage cancers was less than 1 month in several HICs, but up to 4 months for cervical cancer in Mongolia and ovarian cancer in Ecuador, and up to 1 year for breast cancer in Mongolia. INTERPRETATION: The VENUSCANCER project provides the first global picture of patterns of care for three of the most common cancers in women. These findings offer crucial real-world evidence to support the implementation and monitoring of global initiatives on cancer control such as WHO's Global Breast Cancer Initiative and Cervical Cancer Elimination Initiative. Although guideline-consistent treatment has become more accessible for women diagnosed with early-stage tumours in LMICs, the proportion of these women diagnosed early remains far too low. FUNDING: European Research Council Consolidator Grant.

来源:Lancet,查看原文。版权归原作者所有。

引用

  1. Allemani C, Minicozzi P, Morawski B, et al. Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories. Lancet. 2025. PMID: 41138738. doi:10.1016/S0140-6736(25)01383-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。